I'd like to focus my questions to Mr. Nickerson. I think what you brought up is so incredibly interesting because, on the one hand, we Canadians value our humanitarian efforts around the world. You mentioned, for example, the billion dollars we have spent on the vaccine initiative, the $785 million going to the Global Fund. Then, on the other hand, we have these extended patent provisions in the TPP, which will ultimately make drugs cost more. We heard that pretty clearly from the generics and the pharmaceutical industry last week.
I'm wondering if you can speak a little bit about the broken research and development that you mentioned and the relationship between patent extension and potential innovation in pharmaceuticals.